Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Relapsed/Refractory Light Chain Amyloidosis · AL Amyloidosis · Systemic Light Chain Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing GoBroad Boren Hospital, Beijing, Fengtai District, China
Study coordinator · yajing_cart66@126.com

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · San Francisco, United States

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis · Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nashville, United States · Dallas, United States

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

Multiple Myeloma, Refractory to Standard Treatment · Multiple Myeloma, Relapsed · Light Chain Amyloidosis

IsraelRecruitingPHASE2

Jerusalem, Israel

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Relapsed/Refractory AL Amyloidosis

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Beijing, China